Our Story

Since its inception, the RadImmune Therapeutics Leadership Team has been driven by the belief that additional tools are needed for the fight against cancer. To that end, RIT has developed proprietary technology and platform focused on the most challenging to treat cancers. In recognition of the excellent potential displayed in early pre-clinical work, RadImmune Therapeutics was awarded an SBIR Grant by the NIH/NCI thereby validating much of the research to date. RadImmune Therapeutics continues to advance preclinical development programs with the goal of launching a Phase 1 clinical trial late 2019.


Our Approach

Rad Immune Inc. is a start up biotechnology company whose expert multidisciplinary management team is committed to fostering research and development in molecular targeted radiotherapy (formerly known as radio immunotherapy).  Our vision is that molecular targeted radiation therapy has significant untapped potential for offering effective, low toxicity drugs to the oncology market.

Meet the Team

We are a team with diverse skills and interests, united around one thing: Radimmune

Dr. Ekaterina (Kate) Dadachova

Chair of The Scientific  Advisory Board

Dr. Ekaterina (Kate) Dadachova, PhD is a leading nuclear physicist with more than 20 years of experience in this field and Chair in Radiopharmacy at the University of Saskatchewan in Canada. She has developed numerous innovations which have resulted in issued patents.

Dr. David Rickles

Chief Scientific Officer

Dr. David Rickles, MD is a Radiation Oncologist and Assistant Clinical Professor at David Geffen School of Medicine at UCLA.  Through his years of practice and his current research interests, David has moved the field of RIT forward.

Robert Wittig


Robert Wittig has more than 15 years of experience working with growing biotech companies focused on their clinical development programs, business development, finance and operations. Robert has launched a number of successful oncology research programs and companies. In addition, he has held various management positions with AstraZeneca and Pfizer.

Dr. Arturo Casadevall


Dr. Arturo Casadevall, MD, PhD is the Chairman of Molecular Microbiology Department and Bloomberg Distinguished Professor at Johns Hopkins and is the co-inventor of the RIT technology

Jack Hidary

Board Chair

Jack D. Hidary is a successful serial tech entrepreneur and is a regular guest on business and tech channels such as Bloomberg, Fox Business, and CNBC. Jack now serves as Senior Advisor to Google X Labs, the advanced innovation lab of Alphabet/Google, and focuses on the marketplace scaling of X Lab innovations.

Josh Becker

 Director IP/Corp Dev

Josh is a IP expert and experienced technology executive. He has led
Lex Machina (big data for IP law) from a Stanford spin out to an
acquisition by Reed Elsiver. He served in a number of other executive
roles, including corporate development at Agile (sold to Oracle) and a
member of the founding team of Dice.com (DHX).

Paresh Ghelani

Co-Founder and Advisor

Paresh Ghelani is an avid entrepreneur and philanthropist who focuses on solving problems through innovation and entrepreneurship. He is currently active in building and investing in Moon ExpressViome IncDTV Motor Corporation, Ferrate Treatment TechnologiesCasepointRadimmune Therapeutics. He believes in investing and mentoring companies and entrepreneurs who are taking moon shots and changing the world by building breakthrough technologies.